Pharmacological management of osteoporosis in nursing home populations: A systematic review

Journal of the American Geriatrics Society

Volumn 57, Issue 2, 2009, Pages 327-334

  Parikh, Seema ^a,b,c,d   Avorn, Jerry ^b   Solomon, Daniel H ^b  

^a Division of Pharmacoepidemiology and Pharmacoeconomics   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Hebrew Senior Life   (United States)

Author keywords

Medications; Nursing homes; Osteoporosis; Systematic review

Indexed keywords

ALENDRONIC ACID; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; SALCATONIN; VITAMIN D;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; DRUG ACTIVITY; FRACTURE; HUMAN; NURSING HOME; OSTEOPOROSIS; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

AGED; HUMANS; NURSING HOMES; OSTEOPOROSIS;

EID: 58849140825     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2008.02119.x     Document Type: Article

References (42)

1. Zimmerman SI, Girman CJ, Buie VC et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 1999 9 : 151 157.
2. Cali CM, Kiel DP. An epidemiologic study of fall-related fractures among institutionalized older people. J Am Geriatr Soc 1995 43 : 1336 1340.
3. Ooms ME, Vlasman P, Lips P et al. The incidence of hip fractures in independent and institutionalized elderly people. Osteoporos Int 1994 4 : 6 10.
4. Chandler JM, Zimmerman SI, Girman CJ et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 2000 284 : 972 977.
5. Zimmerman S, Chandler JM, Hawkes W et al. Effect of fracture on the health care use of nursing home residents. Arch Intern Med 2002 162 : 1502 1508.
6. Rousculp MD, Long SR, Wang S et al. Economic burden of osteoporosis-related fractures in Medicaid. Value Health 2007 10 : 144 152.
7. Becker C, Loy S, Nikolaus T et al. A follow-up study on fall and fracture incidence in long-term care including the role of formal caregiver time on fall incidence rates. Z Gerontol Geriatr 2006 39 : 292 296.
8. Close P, Neuprez A, Reginster JY. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 2006 7 : 1603 1615.
9. Schousboe JT, Taylor BC, Fink HA et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007 298 : 629 637.
10. Schousboe JT, Ensrud KE, Nyman JA et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005 53 : 1697 1704.
11. Heikinheimo RJ, Inkovaara JA, Harju EJ et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992 51 : 105 110.
12. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992 327 : 1637 1642.
13. Lips P, Graafmans WC, Ooms ME et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996 124 : 400 406.
14. Heikinheimo R, Sievanen H, Jantti P et al. Vitamin D treatment and bone mineral density in the aged. Maturitas 1996 23 (Suppl) : S77 S80.
15. Krieg MA, Jacquet AF, Bremgartner M et al. Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: A longitudinal study. Osteoporos Int 1999 9 : 483 488.
16. Chapuy MC, Pamphile R, Paris E et al. Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study. Osteoporos Int 2002 13 : 257 264.
17. Meyer HE, Smedshaug GB, Kvaavik E et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002 17 : 709 715.
18. Greenspan SL, Schneider DL, McClung MR et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002 136 : 742 746.
19. Flicker L, MacInnis RJ, Stein MS et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J Am Geriatr Soc 2005 53 : 1881 1888.
20. Rojas-Fernandez CH, Lapane KL, MacKnight C et al. Undertreatment of osteoporosis in residents of nursing homes: Population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Endocr Pract 2002 8 : 335 342.
21. Gupta G, Aronow WS. Underuse of procedures for diagnosing osteoporosis and of therapies for osteoporosis in older nursing home residents. J Am Med Dir Assoc 2003 4 : 200 202.
22. Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. J Am Med Dir Assoc 2004 5 : 98 100.
23. Jachna CM, Shireman TI, Whittle J et al. Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers. J Am Geriatr Soc 2005 53 : 1275 1281.
24. Colon-Emeric C, Lyles KW, Levine DA et al. Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int 2007 18 : 553 559.
25. Parikh S, Mogun H, Avorn J et al. Osteoporosis medication use in nursing home patients with fractures in 1 U.S. state. Arch Intern Med 2008 168 : 1111 1115.
26. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 2005 293 : 2257 2264.
27. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. Effect of Vitamin D on falls: A meta-analysis. JAMA 2004 291 : 1999 2006.
28. Gerdhem P, Ringsberg KA, Obrant KJ et al. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of elderly women. Osteoporos Int 2005 16 : 1425 1431.
29. Hansdottir H, Franzson L, Prestwood K et al. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 2004 52 : 779 783.
30. Agrawal S, Krueger DC, Engelke JA et al. Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 2006 54 : 790 795.
31. Thapa PB, Brockman KG, Gideon P et al. Injurious falls in nonambulatory nursing home residents: A comparative study of circumstances, incidence, and risk factors. J Am Geriatr Soc 1996 44 : 273 278.
32. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London : National Institute for Clinical Evidence, 2005.
33. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC : National Osteoporosis Foundation, 2003.
34. Duque G, Mallet L, Roberts A et al. To treat or not to treat, that is the question: proceedings of the Quebec Symposium for the Treatment of Osteoporosis in Long-term Care Institutions, Saint-Hyacinthe, Quebec, November 5, 2004. J Am Med Dir Assoc 2006 7 : 435 441.
35. Wallace RB. Bone health in nursing home residents. JAMA 2000 284 : 1018 1019.
36. Kamel HK, Hussain MS, Tariq S et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000 109 : 326 328.
37. Lips P, Hosking D, Lippuner K et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: An international epidemiological investigation. J Intern Med 2006 260 : 245 254.
38. Dawson-Hughes B, Heaney RP, Holick MF et al. Estimates of optimal vitamin D status. Osteoporos Int 2005 16 : 713 716.
39. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999 282 : 637 645.
40. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 348 : 1535 1541.
41. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995 333 : 1437 1443.
42. Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 2007 146 : 326 339.